Compare Davita Inc (DVA) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Tilray Brands Inc — how do they compare? Davita Inc trades at $175.04 (market cap $11.28B), while Tilray Brands Inc trades at $3.64 (market cap $549.01M). The key difference: Davita Inc is far larger — about 20.5× Tilray Brands Inc's market cap, and Davita Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Tilray Brands Inc for 31 Days on average.
| DVA | TLRY | |
|---|---|---|
Market Cap | $11.28B | $549.01M |
Volume | 650,294 | 3,292,073 |
Sector | Health | Health |
52-Week High | $240.96 | $21.00 |
52-Week Low | $103.87 | $3.57 |
Typical Hold Time | 113 Days | 31 Days |
Enterprise Value | $24.00B | $716.15M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, down 1.87% on the day, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong earnings beats with Q2 2026 EPS of $4.02 exceeding expectations of $3.88, while revenue growth continues from $13.64B in 2025 to projected $14.0B in 2026. Recent developments include expanding value-based care partnerships with Humana, potentially benefiting over 10,000 Medicare Advantage members.
The outlook remains cautiously optimistic with 43% analyst buy ratings and a $235.67 consensus price target suggesting 33% upside. However, rising debt-to-asset ratios (65.55% in 2025) and margin pressures from Q2 2026 create headwinds. Key risks include regulatory changes in healthcare reimbursement and competitive pressures in dialysis services.
Tilray Brands (TLRY) trades at $3.715, down 1.72% on the day, as the stock continues to face significant pressure with bearish technical signals and fundamental challenges. The company reported a substantial net loss of $2.19 billion in 2025 despite $821 million in revenue, with negative cash flow from operations of $94.6 million. Recent earnings have consistently missed expectations, and technical indicators show a bearish trend with the stock trading near key support levels.
While TLRY shows attractive valuation metrics with P/S of 0.45 and P/B of 0.34, the company faces substantial execution risks amid persistent losses and negative cash flow. Analyst sentiment remains cautious with only 25% buy ratings, though the consensus price target of $65.01 suggests significant upside potential if the company can achieve profitability and growth targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
